Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity and chronic weight management. The ...
InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and ...
Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as ...
Sumitomo Pharma America, Inc. (SMPA) today presented new clinical data supporting further development of enzomenib, an investigational, oral selective menin inhibitor being researched for the ...
NTT DATA, a global leader in AI, digital business and technology services, today announced the appointment of Dr. Bratin Saha ...
There will be future cyclones and other such natural cataclysms as the warming equatorial seas result in greater surface ...
MRD-negative response rate in four patients; all remain in response through the longest follow up of 5 monthsFavorable ...
Since 2021, Adhya has served as chief digital officer and global head of digital platforms and experiences at BlackRock. In ...
Rainbows, pickleball and puppies: Inside the ‘enduring activism’ and ‘cautious optimism’ at ASH 2025
People come to Orlando to escape. With Disney World, SeaWorld and Universal Studios all in the area, there are endless ...
Akeso, Inc. (9926.HK) (Akeso or the Company) announced the presentation of a Phase II clinical study that included a ...
As AI adoption grows, not-for-profits face a new test of leadership: turning digital progress into public accountability.
Ernexa is advancing a best-in-class approach using synthetic, allogeneic iMSCs to provide a scalable, off-the-shelf treatment without needing patient-specific cell harvesting. The Company continues to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback